Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

EBNA1 regulates cellular gene expression by binding cellular promoters.

Canaan A, Haviv I, Urban AE, Schulz VP, Hartman S, Zhang Z, Palejev D, Deisseroth AB, Lacy J, Snyder M, Gerstein M, Weissman SM.

Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22421-6. doi: 10.1073/pnas.0911676106. Epub 2009 Dec 22.

2.

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.

Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE.

J Clin Oncol. 2007 May 20;25(15):2078-85.

PMID:
17513813
3.

Recent advances and current challenges in tumor immunology and immunotherapy.

Guinn BA, Kasahara N, Farzaneh F, Habib NA, Norris JS, Deisseroth AB.

Mol Ther. 2007 Jun;15(6):1065-71. Epub 2007 Mar 20. Review.

4.

International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China.

Guinn BA, Norris JS, Farzaneh F, Deisseroth AB.

Cancer Gene Ther. 2007 Feb;14(2):128-38. Epub 2006 Oct 13.

PMID:
17041563
5.

International Society for Cell and Gene Therapy of Cancer (ISCGT) annual meeting: conference overview and introduction to the symposium papers.

Guinn BA, Norris JS, Huang L, Farzaneh F, Kasahara N, Deisseroth AB.

Cancer Immunol Immunother. 2006 Nov;55(11):1406-11. Epub 2006 Jun 17. No abstract available.

PMID:
16783577
7.

Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection.

Brandsma JL, Shlyankevich M, Zhang L, Slade MD, Goodwin EC, Peh W, Deisseroth AB.

J Virol. 2004 Jan;78(1):116-23.

8.

An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells.

Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15101-6. Epub 2003 Nov 25.

9.

Peptides inhibitory for the transcriptional regulatory function of human papillomavirus E2.

Fujii T, Austin D, Guo D, Srimatkandada S, Wang T, Kubushiro K, Masumoto N, Tsukazaki K, Nozawa S, Deisseroth AB.

Clin Cancer Res. 2003 Nov 1;9(14):5423-8.

10.

[Correlation of cell apoptosis induction with expression of human beta5 integrin on hematopoietic cells].

Yin L, Zhao X, Fu S, Garacia-Sanchez F, Deisseroth AB.

Zhonghua Xue Ye Xue Za Zhi. 2001 Jan;22(1):13-6. Chinese.

PMID:
11877043
11.

Correlation of cell proliferation inhibition and apoptosis induction with expression of human beta 5 integrin on hematopoietic cells.

Yin L, Fu S, Zhao X, Garcia-Sanchez F, Deisseroth AB.

Chin Med J (Engl). 1999 Jul;112(7):659-64.

PMID:
11601265
12.

Combinatorial chemistry in cancer drug development.

Leonard KA, Deisseroth AB, Austin DJ.

Cancer J. 2001 Jan-Feb;7(1):79-83. Review.

PMID:
11269651
13.

High and low levels of cottontail rabbit papillomavirus E2 protein generate opposite effects on gene expression.

Fujii T, Brandsma JL, Peng X, Srimatkandada S, Li L, Canaan A, Deisseroth AB.

J Biol Chem. 2001 Jan 12;276(2):867-74.

14.

Human gene marker/therapy clinical protocols.

Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Brenner M, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC, Siegler HF, Barranger JA, Karlsson S, Kohn D, Galpin JE, Raffel C, Hesdorffer C, Ilan J, Cassileth P, O'Shaughnessy J, Kun LE, Das TK, Wong-Staal F, Sobol RE, Haubrich R, Sznol M, Rubin J, Sorcher EJ, Rosenblatt J, Walker R, Brigham K, Vogelzang N, Hersh E, Eck SL.

Hum Gene Ther. 2000 Apr 10;11(6):919-79. No abstract available.

PMID:
10779168
15.

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.

Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE.

J Natl Cancer Inst. 2000 Feb 2;92(3):225-33.

PMID:
10655439
16.

Human gene marker/therapy clinical protocols.

Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Habib NA, et al.

Hum Gene Ther. 1999 Dec 10;10(18):3067-123. No abstract available.

PMID:
10609664
17.

Clinical trials involving multidrug resistance transcription units in retroviral vectors.

Deisseroth AB.

Clin Cancer Res. 1999 Jul;5(7):1607-9. No abstract available.

18.

Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.

Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, Körbling M, Deisseroth AB, Champlin R.

Bone Marrow Transplant. 1999 May;23(10):977-81.

19.

L-selectin expression enhances clonogenesis of CD34+ cord blood progenitors.

Koenig JM, Baron S, Luo D, Benson NA, Deisseroth AB.

Pediatr Res. 1999 Jun;45(6):867-70.

PMID:
10367780
20.

Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.

Chung I, Schwartz PE, Crystal RG, Pizzorno G, Leavitt J, Deisseroth AB.

Cancer Gene Ther. 1999 Mar-Apr;6(2):99-106.

21.

The presence of the Rb c-box peptide in the cytoplasm inhibits p210bcr-abl transforming function.

Guo XY, Balague C, Wang T, Randhawa G, Yuan Z, Bachier C, Greenberger J, Arlinghaus R, Kufe D, Deisseroth AB.

Oncogene. 1999 Feb 25;18(8):1589-95.

22.
23.

Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma.

Bachier CR, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Andreeff M, Cabanillas F, Champlin R, Choudhury R, Berenson R, Heimfeld S, Deisseroth AB.

Leuk Lymphoma. 1999 Jan;32(3-4):279-88.

PMID:
10037025
24.

How to do more with less.

Deisseroth AB.

Cancer J Sci Am. 1998 Nov-Dec;4(6):349-50. No abstract available.

PMID:
9853132
25.

Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.

Guo XY, Cuillerot JM, Wang T, Wu Y, Arlinghaus R, Claxton D, Bachier C, Greenberger J, Colombowala I, Deisseroth AB.

Oncogene. 1998 Aug 20;17(7):825-33.

26.

Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study.

Kornblau SM, Andreeff M, Hu SX, Xu HJ, Patel S, Theriault A, Koller C, Kantarjian H, Estey E, Deisseroth AB, Benedict WF.

Clin Cancer Res. 1998 Aug;4(8):1955-63.

27.

Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation.

Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B, Giles R, Crystal R, Deisseroth AB.

Blood. 1998 Jul 15;92(2):672-82.

28.

Loss of imprinting in disease progression in chronic myelogenous leukemia.

Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, Deisseroth AB, Champlin RC, Feinberg AP.

Blood. 1998 May 1;91(9):3144-7.

29.

Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia.

Deng G, Lane C, Kornblau S, Goodacre A, Snell V, Andreeff M, Deisseroth AB.

Mol Med. 1998 Mar;4(3):158-64.

31.

Human gene marker/therapy clinical protocols.

Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC, et al.

Hum Gene Ther. 1997 Dec 10;8(18):2301-38. No abstract available.

PMID:
9449381
32.

Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells.

Hu G, Liu W, Mendelsohn J, Ellis LM, Radinsky R, Andreeff M, Deisseroth AB.

J Natl Cancer Inst. 1997 Sep 3;89(17):1271-6.

PMID:
9293917
33.
34.

The use of chemotherapy resistance in cancer treatment.

Deisseroth AB, Pizzorno G.

Cancer J Sci Am. 1997 Mar-Apr;3(2):60-9. Review. No abstract available.

PMID:
9099453
35.

Interferon regulatory factor 1 induces the expression of the interferon-stimulated genes.

Henderson YC, Chou M, Deisseroth AB.

Br J Haematol. 1997 Mar;96(3):566-75.

PMID:
9054665
36.

Allogeneic blood stem cell transplantation in advanced hematologic cancers.

Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P, Mehra R, Giralt S, Gajewski J, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Körbling M.

Bone Marrow Transplant. 1997 Mar;19(5):455-60.

38.

Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas.

Sarris AH, Daliani D, Ulmer R, Crow M, Broxmeyer HE, Reiss M, Karasavvas N, Zelenetz AD, Pugh W, Cabanillas F, Deisseroth AB, Duvic M.

Clin Cancer Res. 1997 Feb;3(2):169-77.

39.

Potential role of bcr-abl in the activation of JAK1 kinase.

Henderson YC, Guo XY, Greenberger J, Deisseroth AB.

Clin Cancer Res. 1997 Feb;3(2):145-9.

40.

Gene therapy of solid tumors and hematopoietic neoplasms.

Bachier CR, Deisseroth AB.

Cancer Treat Res. 1997;77:3-26. Review. No abstract available.

PMID:
9071496
41.

Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus.

Przepiorka D, Ippoliti C, Khouri I, Anderlini P, Mehra R, Giralt S, Gajewski J, Fritsche H, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Korbling M.

Transplantation. 1996 Dec 27;62(12):1806-10.

PMID:
8990368
42.

Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy.

Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Deisseroth AB, et al.

Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15346-51. Erratum in: Proc Natl Acad Sci U S A 1997 May 13;94(10):5495.

43.

Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas.

Sarris AH, Daliani D, Ulmer R, Crow M, Broxmeyer HE, Pugh W, Reiss M, Cabanillas F, Deisseroth AB, Duvic M.

Leuk Lymphoma. 1996 Dec;24(1-2):103-10.

PMID:
9049966
44.

Human gene marker/therapy clinical protocols.

Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Tiberghien P, et al.

Hum Gene Ther. 1996 Dec 1;7(18):2287-313. No abstract available.

PMID:
8953320
45.

Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.

Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D, Giralt S, Gajewski J, Fischer H, Fritsche H, Deisseroth AB, Cleary K, Champlin R, Besien K, Andersson B, Maher R, Fitzsimmons W.

Blood. 1996 Dec 1;88(11):4383-9.

46.

Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.

Guo JQ, Lian J, Glassman A, Talpaz M, Kantarjian H, Deisseroth AB, Arlinghaus RB.

Am J Clin Pathol. 1996 Oct;106(4):442-8.

PMID:
8853030
47.

The gene product of CBFB-MYH11.

Claxton D, Xie QS, Patel S, Deisseroth AB, Kornblau S.

Leukemia. 1996 Sep;10(9):1479-85.

PMID:
8751466
48.

Human gene marker/therapy clinical protocols.

Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Aebischer P, et al.

Hum Gene Ther. 1996 Aug 20;7(13):1621-47. No abstract available.

PMID:
8864763
49.

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation in a patient with chronic myelogenous leukemia.

Seong D, Bruner JM, Lee KH, Mirza N, Kwon BD, Lee JH, Lee YY, Ro J, Talpaz M, Champlin R, Deisseroth AB.

Clin Infect Dis. 1996 Aug;23(2):402-3. No abstract available.

PMID:
8842290

Supplemental Content

Loading ...
Support Center